Select coaches
Winger
America wants to sell its own healthcare.
Oxford vaccine
- Thread starter Be Here Now
- Start date
pavarotti1980
Striker
You are right. Pfizer and Moderna are using mRNA technology and the Oxford/AZ is plain old adenovirus vaccine which means they completely incomparable.
Also nowt to do with their healthcare system or the share price which isn't a great mover either way
Last edited:
King Kareoke
Striker
Share price will be affected by a number of things
- They may have factored in the vaccine - AstraZenica pricd has increased a couple of times on early reports
- The UK economic outlook was anticipating a slower recovery (2022)
- Although people are rightly excited by the vaccine because AZ have indicated they will not make huge profits - this is great for us but not great for shareholders as there will not necessarily be a huge dividend paid as a result - therefore the return to shareholders although great in health terms will not necessarily increase the share price
Slim999
Winger
Of course all questions and murkiness will be resolved before we get to the point of mass delivery. ..
These are unusual Times and it's not normal for the Pharmaceutical industry to start flagging up positives in their drug trials- but companies and Governments are spinning the positivity on all of this as they know we need good news
I feel pretty confident that all 3 of these vaccines will be good to go when the fat lady has sung.
Also maybe even the Sputnik vaccine
- don't forget about that one- half the cost of US pharmaceutical products apparently.
They have agreed to sell 20m doses to Argentina
Russia says data on Sputnik Covid vaccine shows 95% efficacy
Country offers to share technology, saying results positive for the entire world
www.theguardian.com
One benefit of adenovirus vaccines ( Ox-AZ + SputnikV) is they can be stored in standard refrigerators, rather than needing very cold freezers .....and that’s a big plus in terms of rolling it out across poorer countries.
Durability , deliverability and lower cost might count for more than pure efficacy in this case
Last edited:
Be Here Now
Winger
British press starting to report it now
They seem determined for it to fail for some reason
They seem determined for it to fail for some reason
Locke's SAFC
Striker
Apparently there is legitimate confusion surrounding the data, including efficacy in the over 55 years age group.
I think their data is to be submitted for peer review within a few weeks, so you'd expect conclusions to be drawn then.
There are also some unusual practices from this trial, such as data being combined from the UK and Brasil trials, but to my untutored eye I fail to see how that would statistically compromise the results.
Time will tell.
Medulla
Striker
Behave man.
Last edited:
Be Here Now
Winger
Just look at the reactions from press when that article by Forbes (the one about the trials on the monkeys) and when the trials were paused.
SurreyMackem
Striker
I don't understand the issue.
If the vaccine is safe and at least 50% effective it should get approval even if the data doesn't back up their 90% claim.
If the vaccine is safe and at least 50% effective it should get approval even if the data doesn't back up their 90% claim.
Medulla
Striker
Let me guess. Was it mild concern at the prospect of a lifesaving vaccine trial programme not going as smoothly as we all hope?
Be Here Now
Winger
Or more the fact ever since this pandemic began the papers in this country every time something remotely positive happens they try and put some kind of negative spin on it.
Medulla
Striker
I think you're mistaking journalism and opinion tbh, but ok
Brian Griffin
Striker
Why would their share price spike when they’re working at cost?
Share prices spike when the markets smell a profit.
pavarotti1980
Striker
Webinar from people involved in the Zoe symptom study regarding the vaccines. Interesting and informative
Medulla
Striker
The issue seems to fundamentally boil down to a lack of clarity and transparency about the AZ trial. In short, people with credibility who have delved into it in detail have suggested that something doesn't really add up based on the fragments of info they've pieced together from press release, statements and trial protocol. For various reasons related to that, it means there are fears that the numbers released might not be the full picture so what we think we know about the efficacy might not be all it seems.
At best, it's confusion bred by a lack of transparency and poor communication that can be solved by the opposite, at worst it's dodginess that could affect approval of the vaccine.
At the moment we don't know, and hopefully when the Phase 3 data are published in the next couple of weeks it is much clearer and more convincing
pavarotti1980
Striker
And that is the danger of people making assumptions without full text data available for analysis and peer review.
I dont think full data has been released for any of the 3 vaccines yet have they?
Medulla
Striker
No. Fingers crossed it comes very soon for all three and there's radical transparency across the board so legitimate questions can be answered.
Another interesting piece on the three vaccine trials by a statistician: A Dose (or more) of Positivity - Reading into AstraZeneca's Interim Analysis Results
Last edited:
FootballFan
Striker
More bad news, looks like somebody was telling porkies as I kind f suspected:
www.ft.com
Doubts raised over AstraZeneca-Oxford vaccine data
Oxford university acknowledges error that forced trial to switch dosing regimens
www.ft.com
